Dietrich Wilhelm Beelen1, Rudolf Trenschel2, Matthias Stelljes3, Christoph Groth3, Tamás Masszi4, Péter Reményi5, Eva-Maria Wagner-Drouet6, Beate Hauptrock6, Peter Dreger7, Thomas Luft7, Wolfgang Bethge8, Wichard Vogel8, Fabio Ciceri9, Jacopo Peccatori9, Friedrich Stölzel10, Johannes Schetelig10, Christian Junghanß11, Christina Grosse-Thie11, Mauricette Michallet12, Hélène Labussiere-Wallet12, Kerstin Schaefer-Eckart13, Sabine Dressler13, Goetz Ulrich Grigoleit14, Stephan Mielke15, Christof Scheid16, Udo Holtick16, Francesca Patriarca17, Marta Medeot17, Alessandro Rambaldi18, Maria Caterina Micò18, Dietger Niederwieser19, Georg-Nikolaus Franke19, Inken Hilgendorf20, Nils Rudolf Winkelmann20, Domenico Russo21, Gérard Socié22, Régis Peffault de Latour22, Ernst Holler23, Daniel Wolff23, Bertram Glass24, Jochen Casper25, Gerald Wulf26, Helge Menzel27, Nadezda Basara27, Maria Bieniaszewska28, Gernot Stuhler29, Mareike Verbeek30, Sandra Grass30, Anna Paola Iori31, Juergen Finke32, Fabio Benedetti33, Uwe Pichlmeier34, Claudia Hemmelmann34, Michael Tribanek34, Anja Klein34, Heidrun Anke Mylius34, Joachim Baumgart34, Monika Dzierzak-Mietla35, Miroslaw Markiewicz36. 1. Department of Bone Marrow Transplantation, West German Cancer Centre, University of Duisburg-Essen, Essen, Germany. Electronic address: dietrich.beelen@uk-essen.de. 2. Department of Bone Marrow Transplantation, West German Cancer Centre, University of Duisburg-Essen, Essen, Germany. 3. Department of Medicine A/Haematology and Oncology, University of Muenster, Muenster, Germany. 4. Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary; St István and St László Hospital of Budapest, Budapest, Hungary. 5. St István and St László Hospital of Budapest, Budapest, Hungary. 6. Third Department of Medicine - Haematology, Internal Oncology & Pneumology, Johannes Gutenberg-University Medical Centre, Mainz, Germany. 7. Department of Medicine V, University of Heidelberg, Heidelberg, Germany. 8. Department of Haematology & Oncology, Medical Centre University Hospital Tuebingen, Tuebingen, Germany. 9. Haematology and Bone Marrow Transplantation Unit, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy. 10. Department of Internal Medicine 1, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany. 11. Department of Haematology, Oncology, and Palliative Care, University Medical Centre, University of Rostock, Rostock, Germany. 12. Department of Haematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France. 13. Clinicum Nuremberg, Paracelsus Medical Private University, Nuremberg, Germany. 14. University Clinic Wuerzburg, Wuerzburg, Germany. 15. University Clinic Wuerzburg, Wuerzburg, Germany; Department of Cell Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital and Institute, Stockholm, Sweden. 16. Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. 17. Haematological Clinic, Unit of Cellular Therapy 'Carlo Melzi', University Hospital, Udine, Italy. 18. Haematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, University of Milan, Bergamo, Italy. 19. University Clinic Leipzig AöR, Leipzig, Germany. 20. Universitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung für Hämatologie und Onkologie, Jena, Germany. 21. Unit of Blood Diseases and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy. 22. Hospital Saint-Louis, Paris, France. 23. University Medical Centre, University of Regensburg, Department of Internal Medicine 3, Regensburg, Germany. 24. Asklepios Clinic Hamburg GmbH, Bone Marrow Transplantation, Asklepios Clinic St Georg, Hamburg, Germany; current affiliation: Clinic for Haematology and Stem Cell Transplantation, HELIOS Clinic Berlin-Buch GmbH, Berlin, Germany. 25. Clinic Oldenburg AöR, Oldenburg, Germany. 26. University Medicine Goettingen, Georg-August-University, Goettingen, Germany. 27. Malteser Hospital St Franziskus-Hospital, Flensburg, Germany. 28. Department of Haematology and Transplantology, Medical University of Gdańsk, Gdansk, Poland. 29. DKD Helios Clinic, Wiesbaden, Germany. 30. Clinic right side of the Isar, Technical University Munich, Munich, Germany. 31. Policlinic Umberto I University La Sapienza, Rome, Italy. 32. University Clinic Freiburg, Medical Clinic, Freiburg, Germany. 33. Policlinic GB Rossi (Borgo Rome), Verona, Italy. 34. medac GmbH, Wedel, Germany. 35. Department of Haematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland. 36. Department of Haematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland; Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.
Abstract
BACKGROUND: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. METHODS: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18-70 years, had acute myeloid leukaemia in first or consecutive complete haematological remission (blast counts <5% in bone marrow) or myelodysplastic syndrome (blast counts <20% in bone marrow), Karnofsky index of 60% or higher, and were indicated for allogeneic HSCT but considered at an increased risk for standard myeloablative preparative regimens based on age (≥50 years), an HSCT-specific comorbidity index of more than 2, or both. Patients were randomly assigned (1:1) to receive either intravenous 10 g/m2 treosulfan daily applied as a 2-h infusion for 3 days (days -4 to -2) or 0·8 mg/kg busulfan applied as a 2-h infusion at 6-h intervals on days -4 and -3. Both groups received 30 mg/m2 intravenous fludarabine daily for 5 days (days -6 to -2). The primary outcome was event-free survival 2 years after HSCT. The non-inferiority margin was a hazard ratio (HR) of 1·3. Efficacy was assessed in all patients who received treatment and completed transplantation, and safety in all patients who received treatment. The study is registered with EudraCT (2008-002356-18) and ClinicalTrials.gov (NCT00822393). FINDINGS:Between June 13, 2013, and May 3, 2016, 476 patients were enrolled (240 in the busulfan group received treatment and transplantation, and in the treosulfan group 221 received treatment and 220 transplanation). At the second preplanned interim analysis (Nov 9, 2016), the primary endpoint was met and trial was stopped. Here we present the final confirmatory analysis (data cutoff May 31, 2017). Median follow-up was 15·4 months (IQR 8·8-23·6) for patients treated with treosulfan and 17·4 months (6·3-23·4) for those treated with busulfan. 2-year event-free survival was 64·0% (95% CI 56·0-70·9) in the treosulfan group and 50·4% (42·8-57·5) in the busulfan group (HR 0·65 [95% CI 0·47-0·90]; p<0·0001 for non-inferiority, p=0·0051 for superiority). The most frequently reported grade 3 or higher adverse events were abnormal blood chemistry results (33 [15%] of 221 patients in the treosulfan group vs 35 [15%] of 240 patients in the busulfan group) and gastrointestinal disorders (24 [11%] patients vs 39 [16%] patients). Serious adverse events were reported for 18 (8%) patients in the treosulfan group and 17 (7%) patients in the busulfan group. Causes of deaths were generally transplantation-related. INTERPRETATION: Treosulfan was non-inferior to busulfan when used in combination with fludarabine as a conditioning regimen for allogeneic HSCT for older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. The improved outcomes in patients treated with the treosulfan-fludarabine regimen suggest its potential to become a standard preparative regimen in this population. FUNDING: medac GmbH.
RCT Entities:
BACKGROUND: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. METHODS: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18-70 years, had acute myeloid leukaemia in first or consecutive complete haematological remission (blast counts <5% in bone marrow) or myelodysplastic syndrome (blast counts <20% in bone marrow), Karnofsky index of 60% or higher, and were indicated for allogeneic HSCT but considered at an increased risk for standard myeloablative preparative regimens based on age (≥50 years), an HSCT-specific comorbidity index of more than 2, or both. Patients were randomly assigned (1:1) to receive either intravenous 10 g/m2 treosulfan daily applied as a 2-h infusion for 3 days (days -4 to -2) or 0·8 mg/kg busulfan applied as a 2-h infusion at 6-h intervals on days -4 and -3. Both groups received 30 mg/m2 intravenous fludarabine daily for 5 days (days -6 to -2). The primary outcome was event-free survival 2 years after HSCT. The non-inferiority margin was a hazard ratio (HR) of 1·3. Efficacy was assessed in all patients who received treatment and completed transplantation, and safety in all patients who received treatment. The study is registered with EudraCT (2008-002356-18) and ClinicalTrials.gov (NCT00822393). FINDINGS: Between June 13, 2013, and May 3, 2016, 476 patients were enrolled (240 in the busulfan group received treatment and transplantation, and in the treosulfan group 221 received treatment and 220 transplanation). At the second preplanned interim analysis (Nov 9, 2016), the primary endpoint was met and trial was stopped. Here we present the final confirmatory analysis (data cutoff May 31, 2017). Median follow-up was 15·4 months (IQR 8·8-23·6) for patients treated with treosulfan and 17·4 months (6·3-23·4) for those treated with busulfan. 2-year event-free survival was 64·0% (95% CI 56·0-70·9) in the treosulfan group and 50·4% (42·8-57·5) in the busulfan group (HR 0·65 [95% CI 0·47-0·90]; p<0·0001 for non-inferiority, p=0·0051 for superiority). The most frequently reported grade 3 or higher adverse events were abnormal blood chemistry results (33 [15%] of 221 patients in the treosulfan group vs 35 [15%] of 240 patients in the busulfan group) and gastrointestinal disorders (24 [11%] patients vs 39 [16%] patients). Serious adverse events were reported for 18 (8%) patients in the treosulfan group and 17 (7%) patients in the busulfan group. Causes of deaths were generally transplantation-related. INTERPRETATION:Treosulfan was non-inferior to busulfan when used in combination with fludarabine as a conditioning regimen for allogeneic HSCT for older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. The improved outcomes in patients treated with the treosulfan-fludarabine regimen suggest its potential to become a standard preparative regimen in this population. FUNDING: medac GmbH.
Authors: Filippo Milano; Jonathan A Gutman; H Joachim Deeg; Eneida R Nemecek; Joachim Baumgart; Laurel Thur; Ann Dahlberg; Rachel B Salit; Corinne Summers; Frederick R Appelbaum; Colleen Delaney Journal: Blood Adv Date: 2020-07-28
Authors: Betül Oran; Kwang Woo Ahn; Caitrin Fretham; Amer Beitinjaneh; Asad Bashey; Attaphol Pawarode; Baldeep Wirk; Bart L Scott; Bipin N Savani; Christopher Bredeson; Daniel Weisdorf; David I Marks; David Rizzieri; Edward Copelan; Gerhard C Hildebrandt; Gregory A Hale; Hemant S Murthy; Hillard M Lazarus; Jan Cerny; Jane L Liesveld; Jean A Yared; Jean Yves-Cahn; Jeffrey Szer; Leo F Verdonck; Mahmoud Aljurf; Marjolein van der Poel; Mark Litzow; Matt Kalaycio; Michael R Grunwald; Miguel Angel Diaz; Mitchell Sabloff; Mohamed A Kharfan-Dabaja; Navneet S Majhail; Nosha Farhadfar; Ran Reshef; Richard F Olsson; Robert Peter Gale; Ryotaro Nakamura; Sachiko Seo; Saurabh Chhabra; Shahrukh Hashmi; Shatha Farhan; Siddhartha Ganguly; Sunita Nathan; Taiga Nishihori; Tania Jain; Vaibhav Agrawal; Ulrike Bacher; Uday Popat; Wael Saber Journal: Transplant Cell Ther Date: 2021-08-14
Authors: Stephan Schaller; Frederico S Martins; Pavel Balazki; Sonja Böhm; Joachim Baumgart; Ralf A Hilger; Dietrich W Beelen; Claudia Hemmelmann; Arne Ring Journal: Br J Clin Pharmacol Date: 2021-10-13 Impact factor: 3.716
Authors: Jochen J Frietsch; Jenny Miethke; Paul Linke; Carl C Crodel; Ulf Schnetzke; Sebastian Scholl; Andreas Hochhaus; Inken Hilgendorf Journal: Bone Marrow Transplant Date: 2022-05-10 Impact factor: 5.174